Pfizer is undergoing a transformation. Since the failure of its promising pill Torcetrapib, all of Pfizer’s operating divisions have been closely examined to decide how they can help the company address the challenges ahead.
Biotherapeutics, believes Dr. Tim Riley, Vice President and Managing Director of the Pharmaceutical Business Operations at Waters Corporation, is rapidly growing. NGP asked him how Water’s mass spectrometry systems help to characterise these therapeutics in order to control their quality and efficacy.
MPI Research’s Dr. David Gauvin discusses predictive methodologies to identify and characterise potential abuse liability issues.
Boro Dropulic, Founder and CEO of Lentigen Corporation, about highly efficient and stable gene delivery offered by Lentiviral vectors.
NGP asked DiLab’s Per Dannhusen what to bear in mind when switching to automated blood sampling.